iVeena Delivery Systems, Inc. is a clinical stage ophthalmology company based in Salt Lake City, Utah. They are focused on developing non-surgical and non-invasive pharmacologic innovations to address unmet needs in the treatment of corneal disease and myopic conditions. Their lead programs include novel proprietary eye drops, IVMED-80 for keratoconus and IVMED-85 for myopia.
iVeena has achieved significant milestones in their research and development efforts. They have been granted Orphan Drug Designation for IVMED-80 and have successfully completed a pre-IND meeting with the FDA. Additionally, they have entered into a strategic licensing agreement with Glaukos Corporation for the development and commercialization of IVMED-80, further validating the potential of their investigational therapies. With a strong focus on transformative disease-modifying advances, iVeena is poised to make a significant impact in the field of ophthalmology.
Generated from the website